Physician profile
Charles Fink Peebles
NPI 1184684862
$960.90
in general payments reported to CMS, 2019-2025
11 companies · $35.69 in 2025
The $35.69 reported for 2025 was less than what a typical Sports Medicine (Podiatrist) provider received nationally (typical 2025 total: $307).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $122 · 2021: $204 · 2022: $91.39 · 2023: $62.43 · 2024: $263 · 2025: $35.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $245 · Food and Beverage: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $245.39 |
| Food and Beverage | $115.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $497.56 | 2019-2022 | |
| Integra Lifesciences Corporation | $245.39 | 2024 | Acell |
| Bioventus LLC | $50.72 | 2019 | |
| Bone Support INC. | $35.69 | 2025 | Ceramentbone Void Filler, Cerament G |
| Astrazeneca Pharmaceuticals Lp | $33.62 | 2023 | |
| Kerecis Limited | $20.37 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.30 | 2019 | |
| Exact Sciences Corporation | $17.19 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.43 | 2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $14.38 | 2023 | |
| Amgen INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Peebles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.